The Gynecologic Oncology Group's role in the treatment of recurrent cervix cancer: Current clinical trials

Gynecologic Oncology

Volumn 110, Issue 3 SUPPL.2, 2008, Pages

  Coleman, Robert L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cisplatin; Paclitaxel; Phase I; Phase II; Phase III clinical studies; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; IPROPLATIN; METHOTREXATE; MITOLACTOL; MONOCLONAL ANTIBODY; NAVELBINE; PACLITAXEL; PLATINUM; TOPOTECAN; VASCULOTROPIN; VINBLASTINE;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; HEALTH CARE ORGANIZATION; HISTORY OF MEDICINE; HUMAN; LUNG TOXICITY; MEDICAL SOCIETY; NAUSEA AND VOMITING; PALLIATIVE THERAPY; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; FEMALE; GYNECOLOGY; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOPLASM RECURRENCE, LOCAL; UTERINE CERVICAL NEOPLASMS;

EID: 50049101436     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.04.017     Document Type: Article

References (17)

1. Monk B.J., Sill M.W., Burger R.A., et al. Phase II trial of bevacizumab in the treatment of recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 108 (2008) S31
2. Thigpen T., Shingleton H., Homesley H., et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 48 (1981) 899-903
3. Bonomi P., Blessing J.A., Stehman F.B., et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 3 (1985) 1079-1085
4. Thigpen J.T., Blessing J.A., DiSaia P.J., et al. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 32 (1989) 198-202
5. McGuire III W.P., Arseneau J., Blessing J.A., et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 7 (1989) 1462-1468
6. Stehman F.B., Blessing J.A., McGehee R., et al. A phase II evaluation of mitolactol in patients with advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 7 (1989) 1892-1895
7. Sutton G.P., Blessing J.A., McGuire W.P., et al. Phase II trial of ifosfamide and mesna in patients with advanced or recurrent squamous carcinoma of the cervix who had never received chemotherapy: a Gynecologic Oncology Group study. Am J Obstet Gynecol 168 (1993) 805-807
8. Omura G.A., Blessing J.A., Vaccarello L., et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 15 (1997) 165-171
9. Buxton E.J., Meanwell C.A., Hilton C., et al. Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer. J Natl Cancer Inst 81 (1989) 359-361
10. Bloss J.D., Blessing J.A., Behrens B.C., et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 20 (2002) 1832-1837
11. Moore D.H., Blessing J.A., McQuellon R.P., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 22 (2004) 3113-3119
12. Fiorica J., Holloway R., Ndubisi B., et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol 85 (2002) 89-94
13. Muderspach L.I., Blessing J.A., Levenback C., et al. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 81 (2001) 213-215
14. Long III H.J., Cross W.G., Wieand H.S., et al. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol 57 (1995) 235-239
15. Long III H.J., Bundy B.N., Grendys Jr. E.C., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 23 (2005) 4626-4633
16. Long III H.J., Monk B.J., Huang H.Q., et al. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 100 (2006) 537-543
17. Monk B.J., Huang H.Q., Cella D., et al. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J Clin Oncol 23 (2005) 4617-4625